FDA
-
-
-
-
-
-
-
CG Oncology adds Christina Rossi to board, Simone Song resigns
-
-
-
-
-
-
-
CG Oncology reports 41.8% complete response rate at 24 months
-
-
-
-
-
-
-
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)
-
-
-
-
-
-
-
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

